NASDAQ:CRNX
Crinetics Pharmaceuticals Inc Stock News
$45.54
-0.530 (-1.15%)
At Close: Jul 02, 2024
7 Biotech Stocks to Boost Your Portfolio to Peak Health
02:11pm, Wednesday, 26'th Jun 2024
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:35pm, Monday, 10'th Jun 2024
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted n
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg)
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.
04:05pm, Thursday, 30'th May 2024
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr.
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
08:00am, Wednesday, 22'nd May 2024
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript
10:09am, Saturday, 11'th May 2024
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Scott Struthers - Founder and Chief Executive
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:38pm, Friday, 10'th May 2024
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
06:36pm, Thursday, 09'th May 2024
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.85 per share a year ago.
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Thursday, 09'th May 2024
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant ( CRN 0 4894 ) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome Will be Presented at ENDO June
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
04:05pm, Thursday, 02'nd May 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 11'th Apr 2024
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted
Under-the-radar biotech bets
01:47pm, Wednesday, 03'rd Apr 2024
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
12:51pm, Wednesday, 20'th Mar 2024
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.